Drug Profile
Zuretinol acetate - Novelion Therapeutics
Alternative Names: 9-cis-Retinol; BBP-551; EB-109; EB-116; QLT-091001; Synthetic retinaldehyde; Synthetic retinoidLatest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator QLT; Retinagenix Therapeutics
- Developer Novelion Therapeutics
- Class Eye disorder therapies; Eye proteins; Retinaldehydes; Retinoids; Small molecules
- Mechanism of Action Acyltransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Leber congenital amaurosis; Retinitis pigmentosa
Highest Development Phases
- Phase III Leber congenital amaurosis; Retinitis pigmentosa
- Phase II Nyctalopia
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-I development in Leber-congenital-amaurosis in Canada (PO, Liquid)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Leber-congenital-amaurosis in Germany (PO, Liquid)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Leber-congenital-amaurosis in Netherlands (PO, Liquid)